Clinical Trial Update: Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating low dose iron chelation to treat oxidative damage in sickle cell disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED